{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:19:42Z","timestamp":1794331182121,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is an increasingly prevalent neurodegenerative disorder, largely sporadic in origin, with limited understanding of age- and region-specific lipid alterations in the human brain. Dysregulation of glycosphingolipid catabolism has been implicated in PD, yet comprehensive spatiotemporal profiling remains sparse. Here, we performed targeted lipidomics across eight anatomically distinct brain regions in post-mortem controls, mid-stage, and late-stage PD cases using high-precision tissue dissection. Each region displayed distinct lipid signatures, with several age-associated alterations\u2014most notably in hexosylceramides, including glucosylceramide. In PD, glycosphingolipids were reduced in subcortical regions but elevated in cortical regions, particularly gangliosides, HexCer, and Hex2Cer, accompanied by increased sphingolipids and decreased phospholipids. The most pronounced mid-stage changes occurred in the putamen, where very long chain ceramide species and plasmalogen PE decreased, then normalising in late-stage disease. Lyso-phosphatidylcholine increased progressively throughout PD progression. Integrating proteomic data, we observed sphingomyelin levels associated with PD-related proteins, while dysregulated mitochondrial function correlated with antioxidant plasmalogens, long-chain ceramides, lyso-phosphatidylcholine, and HexCer in the putamen. These findings highlight region- and stage-specific lipid alterations in PD and their potential convergence with mitochondrial dysfunction.<\/jats:p>","DOI":"10.1038\/s41467-025-65489-2","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:16:50Z","timestamp":1764080210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Multi-omic analysis reveals lipid dysregulation associated with mitochondrial dysfunction in parkinson\u2019s disease brain"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6709-3211","authenticated-orcid":false,"given":"Jenny","family":"H\u00e4llqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-3326","authenticated-orcid":false,"given":"Christina E.","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-4873","authenticated-orcid":false,"given":"Rui","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Doykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wernick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesfer","family":"Al Shahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-281X","authenticated-orcid":false,"given":"James R.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lachica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-3722","authenticated-orcid":false,"given":"Simon","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0892-9204","authenticated-orcid":false,"given":"Simon","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0763-8288","authenticated-orcid":false,"given":"Kevin","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-2661","authenticated-orcid":false,"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-8760","authenticated-orcid":false,"given":"Wendy E.","family":"Heywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"65489_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBDNDC Group","year":"2017","unstructured":"Group, G. B. D. N. D. C. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16, 877\u2013897 (2017).","journal-title":"Lancet Neurol."},{"key":"65489_CR2","doi-asserted-by":"publisher","first-page":"101771","DOI":"10.1016\/j.arr.2022.101771","volume":"83","author":"A Tsamourgelis","year":"2023","unstructured":"Tsamourgelis, A., Swann, P., Chouliaras, L. & O\u2019Brien, J. T. From protein biomarkers to proteomics in dementia with Lewy Bodies. Ageing Res Rev. 83, 101771 (2023).","journal-title":"Ageing Res Rev."},{"key":"65489_CR3","doi-asserted-by":"publisher","first-page":"105580","DOI":"10.1016\/j.nbd.2021.105580","volume":"163","author":"BM Schilder","year":"2022","unstructured":"Schilder, B. M., Navarro, E. & Raj, T. Multi-omic insights into Parkinson\u2019s disease: from genetic associations to functional mechanisms. Neurobiol. Dis. 163, 105580 (2022).","journal-title":"Neurobiol. Dis."},{"key":"65489_CR4","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.arr.2021.101514","volume":"73","author":"SS Chelliah","year":"2022","unstructured":"Chelliah, S. S., Bhuvanendran, S., Magalingam, K. B., Kamarudin, M. N. A. & Radhakrishnan, A. K. Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson\u2019s disease: a systematic review of proteomics studies. Ageing Res Rev. 73, 101514 (2022).","journal-title":"Ageing Res Rev."},{"key":"65489_CR5","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1007\/s00415-023-11781-4","volume":"270","author":"J Yang","year":"2023","unstructured":"Yang, J., Wu, X. & Song, Y. Recent advances in novel mutation genes of Parkinson\u2019s disease. J. Neurol. 270, 3723\u20133732 (2023).","journal-title":"J. Neurol."},{"key":"65489_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41531-023-00558-1","volume":"9","author":"I Kaya","year":"2023","unstructured":"Kaya, I. et al. Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson\u2019s disease primate model. NPJ Parkinsons Dis. 9, 118 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"65489_CR7","doi-asserted-by":"crossref","unstructured":"Flores-Leon, M. & Outeiro, T. F. More than meets the eye in Parkinson\u2019s disease and other synucleinopathies: from proteinopathy to lipidopathy. Acta neuropathologica, 146, 369\u2013385 (2023).","DOI":"10.1007\/s00401-023-02601-0"},{"key":"65489_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109879","volume":"78","author":"ML Allende","year":"2021","unstructured":"Allende, M. L. et al. Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease. Cell. Signal. 78, 109879 (2021).","journal-title":"Cell. Signal."},{"key":"65489_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41531-019-0103-7","volume":"6","author":"S Fanning","year":"2020","unstructured":"Fanning, S., Selkoe, D. & Dettmer, U. Parkinson\u2019s disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis. 6, 3 (2020).","journal-title":"NPJ Parkinsons Dis."},{"key":"65489_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian, S. H. et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099\u20131109 (2019).","journal-title":"Nat. Neurosci."},{"key":"65489_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0006-8993(73)90306-5","volume":"55","author":"L Svennerholm","year":"1973","unstructured":"Svennerholm, L. & Vanier, M. T. The distribution of lipids in the human nervous system. IV. Fatty acid composition of major sphingolipids of human infant brain. Brain Res. 55, 413\u2013423 (1973).","journal-title":"Brain Res."},{"key":"65489_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0022-2275(20)39619-X","volume":"6","author":"JS O\u2019Brien","year":"1965","unstructured":"O\u2019Brien, J. S. & Sampson, E. L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J. Lipid Res 6, 537\u2013544 (1965).","journal-title":"J. Lipid Res"},{"key":"65489_CR13","doi-asserted-by":"crossref","unstructured":"Olsen, A. S. B. & Faergeman, N. J. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 7, 170069 (2017).","DOI":"10.1098\/rsob.170069"},{"key":"65489_CR14","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1111\/febs.12559","volume":"280","author":"G D\u2019Angelo","year":"2013","unstructured":"D\u2019Angelo, G., Capasso, S., Sticco, L. & Russo, D. Glycosphingolipids: synthesis and functions. FEBS J. 280, 6338\u20136353 (2013).","journal-title":"FEBS J."},{"key":"65489_CR15","doi-asserted-by":"crossref","unstructured":"Signorelli, P., Conte, C. & Albi, E. The Multiple Roles of Sphingomyelin in Parkinson\u2019s Disease. Biomolecules 11, 1311 (2021).","DOI":"10.3390\/biom11091311"},{"key":"65489_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fnmol.2019.00200","volume":"12","author":"V Sackmann","year":"2019","unstructured":"Sackmann, V. et al. Inhibition of nSMase2 reduces the transfer of oligomeric alpha-synuclein irrespective of hypoxia. Front. Mol. Neurosci. 12, 200 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"65489_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/ijms14011310","volume":"14","author":"M Kosicek","year":"2013","unstructured":"Kosicek, M. & Hecimovic, S. Phospholipids and Alzheimer\u2019s disease: alterations, mechanisms and potential biomarkers. Int J. Mol. Sci. 14, 1310\u20131322 (2013).","journal-title":"Int J. Mol. Sci."},{"key":"65489_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fnins.2018.00893","volume":"12","author":"JO Ojo","year":"2018","unstructured":"Ojo, J. O. et al. Disruption in brain phospholipid content in a humanized tau transgenic model following repetitive mild traumatic brain injury. Front Neurosci. 12, 893 (2018).","journal-title":"Front Neurosci."},{"key":"65489_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2119\/molmed.2011.00119","volume":"17","author":"N Fabelo","year":"2011","unstructured":"Fabelo, N. et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson\u2019s disease and incidental Parkinson\u2019s disease. Mol. Med 17, 1107\u20131118 (2011).","journal-title":"Mol. Med"},{"key":"65489_CR20","doi-asserted-by":"publisher","unstructured":"McInnes, L. & Healy, J. UMAP: uniform manifold approximation and projection for dimension reduction. https:\/\/doi.org\/10.48550\/arXiv.1802.03426 (2018).","DOI":"10.48550\/arXiv.1802.03426"},{"key":"65489_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.720293","volume":"12","author":"TM Mi","year":"2021","unstructured":"Mi, T. M. et al. Altered functional segregated sensorimotor, associative, and limbic cortical-striatal connections in parkinson\u2019s disease: an fMRI investigation. Front Neurol. 12, 720293 (2021).","journal-title":"Front Neurol."},{"key":"65489_CR22","doi-asserted-by":"publisher","first-page":"fcae065","DOI":"10.1093\/braincomms\/fcae065","volume":"6","author":"A Tomassini","year":"2024","unstructured":"Tomassini, A., Cope, T. E., Zhang, J. & Rowe, J. B. Parkinson\u2019s disease impairs cortical sensori-motor decision-making cascades. Brain Commun. 6, fcae065 (2024).","journal-title":"Brain Commun."},{"key":"65489_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/jnnp-2018-320157","volume":"90","author":"J Pasquini","year":"2019","unstructured":"Pasquini, J. et al. Clinical implications of early caudate dysfunction in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 90, 1098\u20131104 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"65489_CR24","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, J. R., Zang, Y. F. & Wu, T. Consistent decreased activity in the putamen in Parkinson\u2019s disease: a meta-analysis and an independent validation of resting-state fMRI. Gigascience 7, giy071 (2018).","DOI":"10.1093\/gigascience\/giy071"},{"key":"65489_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S0317167100014232","volume":"40","author":"MM Lewis","year":"2013","unstructured":"Lewis, M. M. et al. The role of the cerebellum in the pathophysiology of Parkinson\u2019s disease. Can. J. Neurol. Sci. 40, 299\u2013306 (2013).","journal-title":"Can. J. Neurol. Sci."},{"key":"65489_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fneur.2020.00127","volume":"11","author":"L Solstrand Dahlberg","year":"2020","unstructured":"Solstrand Dahlberg, L., Lungu, O. & Doyon, J. Cerebellar contribution to motor and non-motor functions in Parkinson\u2019s Disease: a meta-analysis of fMRI findings. Front Neurol. 11, 127 (2020).","journal-title":"Front Neurol."},{"key":"65489_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/brain\/aws360","volume":"136","author":"T Wu","year":"2013","unstructured":"Wu, T. & Hallett, M. The cerebellum in Parkinson\u2019s disease. Brain 136, 696\u2013709 (2013).","journal-title":"Brain"},{"key":"65489_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"65489_CR29","doi-asserted-by":"crossref","unstructured":"Marchese, S. M., Farinelli, V., Bolzoni, F., Esposti, R. & Cavallari, P. Overview of the cerebellar function in anticipatory postural adjustments and of the compensatory mechanisms developing in neural dysfunctions. in Appl. Sci. 10, 5088 (2020).","DOI":"10.3390\/app10155088"},{"key":"65489_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41531-025-00931-2","volume":"11","author":"WH Ren","year":"2025","unstructured":"Ren, W. H. et al. Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD. NPJ Parkinsons Dis. 11, 83 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"65489_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40478-022-01424-6","volume":"10","author":"CE Toomey","year":"2022","unstructured":"Toomey, C. E. et al. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson\u2019s. Acta Neuropathol. Commun. 10, 134 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"65489_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101772","volume":"187","author":"PJ Carling","year":"2020","unstructured":"Carling, P. J. et al. Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson\u2019s disease. Prog. Neurobiol. 187, 101772 (2020).","journal-title":"Prog. Neurobiol."},{"key":"65489_CR33","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/cercor\/bhi044","volume":"15","author":"N Raz","year":"2005","unstructured":"Raz, N. et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb. Cortex 15, 1676\u20131689 (2005).","journal-title":"Cereb. Cortex"},{"key":"65489_CR34","doi-asserted-by":"publisher","first-page":"e0234255","DOI":"10.1371\/journal.pone.0234255","volume":"15","author":"X Feng","year":"2020","unstructured":"Feng, X. et al. Brain regions vulnerable and resistant to aging without Alzheimer\u2019s disease. PloS one 15, e0234255 (2020).","journal-title":"PloS one"},{"key":"65489_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 2, 433\u2013438 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"65489_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2018.02.028","volume":"67","author":"PJ Hallett","year":"2018","unstructured":"Hallett, P. J. et al. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol. aging 67, 189\u2013200 (2018).","journal-title":"Neurobiol. aging"},{"key":"65489_CR37","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1194\/jlr.RA119000157","volume":"60","author":"R Sidhu","year":"2019","unstructured":"Sidhu, R. et al. N-acyl-O-phosphocholineserines: structures of a novel class of lipids that are biomarkers for Niemann-Pick C1 disease. J. Lipid Res 60, 1410\u20131424 (2019).","journal-title":"J. Lipid Res"},{"key":"65489_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1388-1981(02)00331-1","volume":"1585","author":"BJ Pettus","year":"2002","unstructured":"Pettus, B. J., Chalfant, C. E. & Hannun, Y. A. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys. Acta 1585, 114\u2013125 (2002).","journal-title":"Biochim Biophys. Acta"},{"key":"65489_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.25729","volume":"29","author":"SK Abbott","year":"2014","unstructured":"Abbott, S. K. et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson\u2019s disease. Mov. Disord. 29, 518\u2013526 (2014).","journal-title":"Mov. Disord."},{"key":"65489_CR40","doi-asserted-by":"publisher","first-page":"109139","DOI":"10.1016\/j.ymgme.2025.109139","volume":"145","author":"A Lake","year":"2025","unstructured":"Lake, A., Saville, J. & Fuller, M. Sphingolipid de novo synthesis is upregulated in a macrophage model of Gaucher disease. Mol. Genet. Metab. 145, 109139 (2025).","journal-title":"Mol. Genet. Metab."},{"key":"65489_CR41","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nchembio.1059","volume":"8","author":"RD Sentelle","year":"2012","unstructured":"Sentelle, R. D. et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. Chem. Biol. 8, 831\u2013838 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"65489_CR42","doi-asserted-by":"crossref","unstructured":"Vos, M. et al. Ceramide accumulation induces mitophagy and impairs beta-oxidation in PINK1 deficiency. Proc. Natl. Acad. Sci. USA. 118, 703\u2013704 (2021).","DOI":"10.1073\/pnas.2025347118"},{"key":"65489_CR43","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0028-3908(86)90206-6","volume":"25","author":"M Hadjiconstantinou","year":"1986","unstructured":"Hadjiconstantinou, M., Rossetti, Z. L., Paxton, R. C. & Neff, N. H. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology 25, 1075\u20131077 (1986).","journal-title":"Neuropharmacology"},{"key":"65489_CR44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.256.5058.843","volume":"256","author":"JS Schneider","year":"1992","unstructured":"Schneider, J. S. et al. Recovery from experimental Parkinsonism in primates with GM1 ganglioside treatment. Science 256, 843\u2013846 (1992).","journal-title":"Science"},{"key":"65489_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jns.2012.10.024","volume":"324","author":"JS Schneider","year":"2013","unstructured":"Schneider, J. S. et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson\u2019s disease patients. J. Neurol. Sci. 324, 140\u2013148 (2013).","journal-title":"J. Neurol. Sci."},{"key":"65489_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2010.02.009","volume":"292","author":"JS Schneider","year":"2010","unstructured":"Schneider, J. S., Sendek, S., Daskalakis, C. & Cambi, F. GM1 ganglioside in Parkinson\u2019s disease: Results of a five year open study. J. Neurol. Sci. 292, 45\u201351 (2010).","journal-title":"J. Neurol. Sci."},{"key":"65489_CR47","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper, J. et al. Lipid pathway dysfunction is prevalent in patients with Parkinson\u2019s disease. Brain 145, 3472\u20133487 (2022).","journal-title":"Brain"},{"key":"65489_CR48","doi-asserted-by":"publisher","first-page":"730829","DOI":"10.3389\/fphys.2021.730829","volume":"12","author":"JC Bozelli Jr.","year":"2021","unstructured":"Bozelli, J. C. Jr., Azher, S. & Epand, R. M. Plasmalogens and chronic inflammatory diseases. Front Physiol. 12, 730829 (2021).","journal-title":"Front Physiol."},{"key":"65489_CR49","doi-asserted-by":"publisher","first-page":"633022","DOI":"10.3389\/fnins.2021.633022","volume":"15","author":"Z Wu","year":"2021","unstructured":"Wu, Z., Wu, S., Liang, T. & Wang, L. Lipoprotein-associated phospholipase A2 is a risk factor for patients with Parkinson\u2019s Disease. Front Neurosci. 15, 633022 (2021).","journal-title":"Front Neurosci."},{"key":"65489_CR50","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bbalip.2013.11.013","volume":"1841","author":"NI Hollie","year":"2014","unstructured":"Hollie, N. I. et al. Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function. Biochim. Biophys. Acta 1841, 888\u2013895 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"65489_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae182","volume":"11","author":"C Zhao","year":"2024","unstructured":"Zhao, C. et al. Lysophosphatidylcholine binds alpha-synuclein and prevents its pathological aggregation. Natl. Sci. Rev. 11, nwae182 (2024).","journal-title":"Natl. Sci. Rev."},{"key":"65489_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41531-025-00902-7","volume":"11","author":"C Mu","year":"2025","unstructured":"Mu, C. et al. Lysophosphatidylcholine promoting alpha-Synuclein aggregation in Parkinson\u2019s disease: disrupting GCase glycosylation and lysosomal alpha-Synuclein degradation. NPJ Parkinsons Dis. 11, 47 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"65489_CR53","doi-asserted-by":"crossref","unstructured":"Han, X. et al. Lipidomics: comprehensive mass spectrometry of lipids, (John Wiley & Sons, Incorporated, Hoboken, New Jersey, 2016).","DOI":"10.1002\/9781119085263"},{"key":"65489_CR54","doi-asserted-by":"crossref","unstructured":"Magny, R. et al. Lipid annotation by combination of UHPLC-HRMS (MS), molecular networking, and retention time prediction: application to a lipidomic study of in vitro models of dry eye disease. Metabolites 10, 225 (2020).","DOI":"10.3390\/metabo10060225"},{"key":"65489_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jimd.12425","volume":"45","author":"FM Vaz","year":"2022","unstructured":"Vaz, F. M. et al. An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin\/cardiolipin ratio. J. Inherit. Metab. Dis. 45, 29\u201337 (2022).","journal-title":"J. Inherit. Metab. Dis."},{"key":"65489_CR56","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/nbt.2377","volume":"30","author":"MC Chambers","year":"2012","unstructured":"Chambers, M. C. et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30, 918\u2013920 (2012).","journal-title":"Nat. Biotechnol."},{"key":"65489_CR57","doi-asserted-by":"crossref","unstructured":"Jolly, E. et al. Pymer4: connecting R and Python for linear mixed modeling. J. Open Source Softw. 3, 862 (2018).","DOI":"10.21105\/joss.00862"},{"key":"65489_CR58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65489-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T03:01:37Z","timestamp":1764471697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65489"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65489-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.18.604051","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have any competing interests to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10490"}}